XM does not provide services to residents of the United States of America.

XM does not provide services to residents of the United States of America.
S
S

Sage

News

Reuters - 3 days ago

U.S. Microstrategy, Snowflake, Target

CORRECTED-U.S. RESEARCH ROUNDUP-Microstrategy, Snowflake, Target Corrects company name to Aclaris Therapeutics in table entry for Cantor Fitzgerald's research action Nov 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Microstrategy, Snowflake, and Target, on Thursday. HIGHLIGHTS * Dycom Industries Inc DY.N : D.A.
N
N
S
S
J
R
Reuters - 4 days ago

U.S. STOCKS Williams-Sonoma, Inspire Medical

BUZZ-U.S. STOCKS ON THE MOVE-Williams-Sonoma, Inspire Medical Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes dropped on Wednesday, as AI giant Nvidia lost ground ahead of quarterly results, retailer Target's shares plunged following weak forecasts and heightened Russia-Ukraine tensions impacted investor sentiment.
F
J
N
S
U
U
A
C
A
C
Reuters - 4 days ago

U.S. STOCKS Williams-Sonoma, Inspire Medical, Lemonade Inc

BUZZ-U.S. STOCKS ON THE MOVE-Williams-Sonoma, Inspire Medical, Lemonade Inc Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were little changed on Wednesday, as investors awaited AI giant Nvidia's quarterly results, while also eyeing rising geopolitical tensions between Russia and Ukraine.
F
S
U
U
C
C
Reuters - 4 days ago

U.S. STOCKS Comcast, Wix.com, Flex

BUZZ-U.S. STOCKS ON THE MOVE-Comcast, Wix.com, Flex Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures treaded water on Wednesday as investors awaited Nvidia's quarterly results, seen as pivotal in sustaining the AI behemoth's record rally, while retailer Target's shares fell after a disappointing forecast.
A
C
F
N
S
C
C
Reuters - 4 days ago

Sage Therapeutics declines after stopping development of rare disease drug

BUZZ-Sage Therapeutics declines after stopping development of rare disease drug ** Drug developer Sage Therapeutics' SAGE.O shares fall 4.3% to $4.70 premarket ** Company says it will stop further development of its experimental drug, dalzanemdor, after it did not meet main goal in a mid-stage trial ** Sage was testing the drug to treat cognitive i
S
Reuters - 4 days ago

Sage to abandon development of neurological disorder drug after multiple failures

UPDATE 3-Sage to abandon development of neurological disorder drug after multiple failures Adds graphic, updates shares, adds company comment in paragraph 4, analyst comment in paragraph 5 By Mariam Sunny Nov 20 (Reuters) - Sage Therapeutics SAGE.O said on Wednesday it would stop the development of its experimental drug following the latest failure in a study testing it in patients with Huntington's disease, a rare neurological disorder.
B
S
Reuters - 4 days ago

Sage Therapeutics' rare disease drug fails mid-stage study

Sage Therapeutics' rare disease drug fails mid-stage study Nov 20 (Reuters) - Sage Therapeutics SAGE.O said on Wednesday its experimental drug failed to meet the main goal in a mid-stage study testing the drug in patients with a rare, genetic neurological condition called Huntington's disease. Reporting by Mariam Sunny in Bengaluru; Editing by Shin
S
Reuters - 3 weeks ago

Sage Therapeutics CFO Kimi Iguchi resigns from position

BRIEF-Sage Therapeutics CFO Kimi Iguchi resigns from position Nov 1 (Reuters) - SAGE Therapeutics Inc SAGE.O : SAGE THERAPEUTICS: RESIGNATION OF KIMI IGUCHI FROM HER POSITION AS CFO OF CO Source text: [ID:n0001193125-24-249830] Further company coverage: SAGE.O
S
Reuters - 4 weeks ago

SAGE Therapeutics Inc reports results for the quarter ended in January 1 - Earnings Summary

SAGE Therapeutics Inc reports results for the quarter ended in January 1 - Earnings Summary SAGE Therapeutics Inc SAGE.OQ reported a quarterly adjusted loss of $1.53​​ per share for the quarter ended January 1, higher than the same quarter last year, when the company reported EPS of $-3.37. The mean expectation of nineteen analysts for the quarter was for a loss of $1.53 per share.
S
Reuters - 4 weeks ago

SAGE Therapeutics Inc <SAGE.OQ> expected to post a loss of $1.53 a share - Earnings Preview

SAGE Therapeutics Inc expected to post a loss of $1.53 a share - Earnings Preview SAGE Therapeutics Inc SAGE.OQ SAGE.O is expected to show a rise in quarterly revenue when it reports results on October 29 for the period ending September 30 2024 The Cambridge Massachusetts-based company is expected to report a 297.7% increase in revenue to $10.802 million from $2.72 million a year ago, according to the mean estimate from 19 analysts, based on LSEG data.
S
Reuters - 1 month ago

U.S. STOCKS Avery Dennison, Snap-On, Avadel Pharma

BUZZ-U.S. STOCKS ON THE MOVE-Avery Dennison, Snap-On, Avadel Pharma Wall Street rose on Thursday, with the S&P 500 and the Dow briefly reaching record highs, as chip stocks surged on TSMC's upbeat forecast and stronger-than-expected monthly retail sales indicated a robust U.S. consumer. .N At 13:36 ET, the Dow Jones Industrial Average .DJI was up 0
A
B
C
E
I
N
N
S
S
S
U
U
U
U
A
E
Reuters - 1 month ago

U.S. STOCKS Avery Dennison, Snap-On, Avadel Pharma

BUZZ-U.S. STOCKS ON THE MOVE-Avery Dennison, Snap-On, Avadel Pharma Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street gained on Thursday, with the S&P 500 and the Dow touching intraday record highs, driven by TSMC's upbeat forecast and a bigger-than-expected rise in monthly retail sales indicating a strong U.S.
A
B
C
E
I
N
N
R
S
S
S
U
U
U
U
T
U
W
W
A
E
M
S
Reuters - 1 month ago

Sage to lay off more than half of R&D team, shares fall

BUZZ-Sage to lay off more than half of R&D team, shares fall ** Sage Therapeutics' shares SAGE.O fall 5.5% to $6.87 in morning trade ** Co says it will lay off more than 165 employees, including more than half of its R&D team, as part of reorganization plan ** To prioritize launch of postpartum depression pill Zurzuvae, which has been jointly devel
B
S
Reuters - 1 month ago

SAGE Therapeutics Approved Separation Of CFO Kimi Iguchi And Anne Cook, Senior VP, General Counsel, And Secretary

BRIEF-SAGE Therapeutics Approved Separation Of CFO Kimi Iguchi And Anne Cook, Senior VP, General Counsel, And Secretary Oct 17 (Reuters) - SAGE Therapeutics Inc SAGE.O : SAGE THERAPEUTICS: APPROVED SEPARATION OF KIMI IGUCHI, CFO, AND ANNE MARIE COOK, SENIOR VP, GENERAL COUNSEL, AND SECRETARY Source text for Eikon: [ID:n0001193125-24-238425] Further
S
Reuters - 1 month ago

SAGE Therapeutics Says To Reduce Workforce By About 33%

BRIEF-SAGE Therapeutics Says To Reduce Workforce By About 33% Oct 17 (Reuters) - SAGE Therapeutics Inc SAGE.O : SAGE THERAPEUTICS ANNOUNCES STRATEGIC REORGANIZATION TO PRIORITIZE ZURZUVAE® COMMERCIALIZATION AND FOCUS ITS DEVELOPMENT PORTFOLIO SAGE THERAPEUTICS INC - TO REDUCE WORKFORCE BY APPROXIMATELY 33% SAGE THERAPEUTICS INC - REORGANIZATION TO
S
Reuters - 1 month ago

Sage Therapeutics' CFO to leave, drugmaker to lay off over 165 employees

UPDATE 2-Sage Therapeutics' CFO to leave, drugmaker to lay off over 165 employees Adds details on CFO leaving company in paragraphs 1, 3 and background in paragraphs 8-10 Oct 17 (Reuters) - Sage Therapeutics SAGE.O said on Thursday its finance chief will leave the company and the drugmaker plans to lay off more than 165 employees as part of a reorganization plan that aims to focus on the launch of its postpartum depression pill.
B
S
Reuters - 1 month ago

Sage Therapeutics to lay off more than 165 employees

Sage Therapeutics to lay off more than 165 employees Oct 17 (Reuters) - Sage Therapeutics SAGE.O said on Thursday it will lay off more than 165 employees or about 33% of the company's total workforce. Reporting by Sriparna Roy in Bengaluru; Editing by Shounak Dasgupta
S
Reuters - 1 month ago

U.S. Autozone, State Street, UnitedHealth

U.S. RESEARCH ROUNDUP-Autozone, State Street, UnitedHealth Oct 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Autozone, State Street and UnitedHealth, on Wednesday. HIGHLIGHTS * Autozone Inc AZO.N : Roth MKM resumes coverage with buy rating; price target $3,634 * Goldman Sachs GS.N : Barclays raises target price to $588 from $565 * ServiceNow Inc NOW.N : Jefferies raises target price to $1,100 from $900 * State St
C
G
S
T
F
G
S
A
Reuters - 2 months ago

U.S. Aflac, Lincoln National, Prudential Financial

U.S. RESEARCH ROUNDUP-Aflac, Lincoln National, Prudential Financial Oct 9 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Aflac, Lincoln National and Prudential Financial, on Wednesday. HIGHLIGHTS * Aflac Inc AFL.N : TD Cowen initiates coverage with hold rating; price target $102 * Corebridge Financial Inc CRBG.N : TD Cowen initiates coverage with buy rating * Lincoln National Corp LNC.N : TD Cowen initiates coverage
A
B
G
H
N
P
S
S
S
A
V
A
A
E
G
L
M
Reuters - 2 months ago

U.S. STOCKS Nvidia, Roblox, Honeywell

BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Roblox, Honeywell Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes opened higher on Tuesday, as investors shifted their attention to the upcoming third-quarter earnings season and inflation data for hints on the Federal Reserve's future rate decisions.
C
M
M
N
Q
S
L
R
W
U
U
E
S
T

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.